Search Results

There are 1740 results for: content related to: Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen

  1. Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 3, March 2011, Pages: 368–377, Li Zhu, Anna Persson, Lisa Mahnke, Timothy Eley, Tong Li, Xiaohui Xu, Sangeeta Agarwala, Jeffrey Dragone and Richard Bertz

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010367651

  2. Atazanavir for the Treatment of Human Immunodeficiency Virus Infection

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 12, December 2004, Pages: 1732–1747, Dr. Anthony J. Busti, Dr. Ronald G. Hall II and Dr. David M. Margolis

    Article first published online : 16 JAN 2012, DOI: 10.1592/phco.24.17.1732.52347

  3. Discovery and Development of Atazanavir

    Antiviral Drugs: From Basic Discovery through Clinical Trials

    Awny Farajallah, R. Todd Bunch, Nicholas A. Meanwell, Pages: 1–17, 2011

    Published Online : 20 JUN 2011, DOI: 10.1002/9780470929353.ch1

  4. Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs

    Journal of Mass Spectrometry

    Volume 48, Issue 9, September 2013, Pages: 1019–1031, Changfu Cheng, Sunanda Vedananda, Lijun Wu, Scott Harbeson, Virginia Braman and Roger Tung

    Article first published online : 30 AUG 2013, DOI: 10.1002/jms.3247

  5. Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1376–1402, Diana M. Brainard, Larissa A. Wenning, Julie A. Stone, John A. Wagner and Marian Iwamoto

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270010387428

  6. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line

    Journal of Neuroscience Research

    Volume 87, Issue 4, March 2009, Pages: 1023–1036, Jason A. Zastre, Gary N.Y. Chan, Patrick T. Ronaldson, Manisha Ramaswamy, Pierre O. Couraud, Ignacio A. Romero, Babette Weksler, Moise Bendayan and Reina Bendayan

    Article first published online : 14 OCT 2008, DOI: 10.1002/jnr.21898

  7. You have full text access to this OnlineOpen article
    Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents

    British Journal of Clinical Pharmacology

    Volume 72, Issue 6, December 2011, Pages: 940–947, Frantz Foissac, Stéphane Blanche, Catherine Dollfus, Déborah Hirt, Ghislaine Firtion, Corinne Laurent, Jean-Marc Treluyer and Saïk Urien

    Article first published online : 9 NOV 2011, DOI: 10.1111/j.1365-2125.2011.04035.x

  8. Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 3, March 2006, Pages: 341–346, Dr. Desiree L. Tomilo, Dr. Patrick F. Smith, Dr. Abayomi B. Ogundele, Dr. Robin Difrancesco, Dr. Charles S. Berenson, Ellana Eberhardt, Edward Bednarczyk and Dr. Gene D. Morse

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.26.3.341

  9. Pharmacokinetics of Concurrent Administration of Fosamprenavir and Atazanavir without Ritonavir in Human Immunodeficiency Virus-Negative Subjects

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 8, August 2009, Pages: 937–942, Dr. MaryPeace McRae, Dr. Patrick G. Clay, Dr. Peter L. Anderson and Dr. Alan G. Glaros

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.29.8.937

  10. You have full text access to this OnlineOpen article
    Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure

    HIV Medicine

    Volume 9, Issue 4, April 2008, Pages: 239–245, S Di Giambenedetto, A De Luca, P Villani, A Bacarelli, E Ragazzoni, M Regazzi, R Cauda and P Navarra

    Article first published online : 23 MAR 2008, DOI: 10.1111/j.1468-1293.2008.00555.x

  11. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

    HIV Medicine

    Volume 15, Issue 5, May 2014, Pages: 301–310, J Baril, B Conway, P Giguère, N Ferko, S Hollmann and JB Angel

    Article first published online : 9 DEC 2013, DOI: 10.1111/hiv.12118

  12. You have full text access to this OnlineOpen article
    HIV Protease Inhibitor-Specific Alterations in Human Adipocyte Differentiation and Metabolism

    Obesity

    Volume 14, Issue 6, June 2006, Pages: 994–1002, Roy J. Kim, Camella G. Wilson, Martin Wabitsch, Mitchell A. Lazar and Claire M. Steppan

    Article first published online : 6 SEP 2012, DOI: 10.1038/oby.2006.114

  13. Effects of Esomeprazole on the Pharmacokinetics of Atazanavir and Fosamprenavir in a Patient with Human Immunodeficiency Virus Infection

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 4, April 2006, Pages: 511–514, Jennifer J. Kiser, Kenneth A. Lichtenstein, Peter L. Anderson and Courtney V. Fletcher

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.26.4.511

  14. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients

    HIV Medicine

    Volume 14, Issue 7, August 2013, Pages: 449–452, A Jansen, EPH Colbers, AJAM van der Ven, C Richter, JK Rockstroh, JC Wasmuth, M van Luin and DM Burger

    Article first published online : 18 MAR 2013, DOI: 10.1111/hiv.12029

  15. You have full text access to this OnlineOpen article
    Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

    HIV Medicine

    Volume 10, Issue 5, May 2009, Pages: 318–327, F Tomaka, E Lefebvre, V Sekar, B Van Baelen, T Vangeneugden, A Vandevoorde and G Diego Miralles

    Article first published online : 5 FEB 2009, DOI: 10.1111/j.1468-1293.2008.00690.x

  16. Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry

    Journal of Mass Spectrometry

    Volume 48, Issue 6, June 2013, Pages: 640–650, Changfu Cheng, Richard Gallegos, Gary Bridson, Lijun Wu, Scott Harbeson, Robert Zelle and Roger Tung

    Article first published online : 22 MAY 2013, DOI: 10.1002/jms.3201

  17. Lipid-Lowering Efficacy and Safety After Switching to Atazanavir-Ritonavir-Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 3, March 2008, Pages: 323–330, Dr. Sean T. Nguyen, Dr. Susan A. Eaton, Dr. Amy M. Bain, Dr. Anita P. Rahman, Dr. Kenna D. Payne, Dr. Roger Bedimo, Dr. Jon D. Herrington, Dr. Darego O. Maclayton, Dr. Maria C. Rodriguez-Barradas and Dr. Anthony J. Busti

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.28.3.323

  18. An Update and Review of Antiretroviral Therapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 8, August 2006, Pages: 1111–1133, Frank J. Piacenti

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.26.8.1111

  19. You have full text access to this OnlineOpen article
    Interactions between protease inhibitors and acid-reducing agents: a systematic review

    HIV Medicine

    Volume 8, Issue 6, September 2007, Pages: 335–345, L Béïque, P Giguère, C La Porte and J Angel

    Article first published online : 26 JUL 2007, DOI: 10.1111/j.1468-1293.2007.00482.x

  20. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

    HIV Medicine

    E Martinez, A Gonzalez-Cordon, E Ferrer, P Domingo, E Negredo, F Gutierrez, J Portilla, A Curran, D Podzamczer, J Murillas, JI Bernardino, I Santos, JA Carton, J Peraire, J Pich, I Perez, JM Gatell and for the ATADAR Study Group

    Article first published online : 12 JAN 2014, DOI: 10.1111/hiv.12121